(Q34207923)

English

Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Stephanie Daignault

5

object named as

Stephanie Daignault

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Kathleen M Woods Ignatoski

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Judah Friedman

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

June Escara-Wilke

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Xiaohua Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Rodney L Dunn

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

David C Smith

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Evan T Keller

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Journal of Interferon and Cytokine Research

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

105-112

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Recommendations for zoledronic acid treatment of patients with bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

The IKK NF-kappa B system: a treasure trove for drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

The role of osteoclastic activity in prostate cancer skeletal metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Interleukin-6 and prostate cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Osteoprotegerin and rank ligand expression in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

5 July 2018

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956618

28 October 2018

Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteocalcin: a potential marker of metastatic bone disease and response to treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum osteocalcin concentration in patients with prostatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The association between measures of progression and survival in castrate-metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

1 reference

https://pubmed.ncbi.nlm.nih.gov/19014338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1089/JIR.2008.0024

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34207923&oldid=1752736307"